Aclarion, Inc. (ACON)
Nasdaq · Healthcare · Health Information Services
$2.34−1.68%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $6.7M
- 52-week range
- $1.95 – $12.03
- 52-week change
- −68.89%
- EPS (trailing)
- −$7.38
- Analyst rating
- 1.0 Strong buy
Fiscal year to Dec 2025
- Revenue
- $76K (+65.62%)
- Net income
- −$7.2M
- Operating margin
- −9312.6%
- Diluted EPS
- −$13.61
- Free cash flow
- −$7.2M
From the company’s annual report on SEC EDGAR.
About Aclarion, Inc.
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform.
Headquarters: Broomfield, United States · 10 employees · aclarion.com